Portfolio
Optimizer

Assess the probability of technical and regulatory success (PTRS) and phase transition probability of your pipeline programs in an objective and efficient way. Understand the supporting rationale, track the evolution of PTRS based on key events, and make portfolio and program-level decisions

Portfolio optimizer

Bring an objective, data-driven perspective in your portfolio management, and review your pipeline in the context of competitive programs and past experience

Assess the drivers for the Probabilty of Technical and Regulatory Success, as well as Phase Transition Probability

Portfolio optimizer

Customer Use Case

  • Objective
  • Intelligencia's Advantage
  • Impact
Download PDF

Objective

The Portfolio Strategy team of a prominent mid-size Pharma company had been seeking to implement a systematic way to review the PTRS (Probability of Technical and Regulatory Success) of all its programs. Initial focus was on oncology, but over time, they also expanded this approach to other TAs.

Previously, the company had relied on disparate analysis including the estimates provided by the program teams, analytics performed on internal historic data, and industry- wide historical benchmarks.

Objective

The Portfolio Strategy team of a prominent mid-size Pharma company had been seeking to implement a systematic way to review the PTRS (Probability of Technical and Regulatory Success) of all its programs. Initial focus was on oncology, but over time, they also expanded this approach to other TAs.

Previously, the company had relied on disparate analysis including the estimates provided by the program teams, analytics performed on internal historic data, and industry- wide historical benchmarks.

Intelligencia's Advantage

Intelligencia’s Porfolio Optimizer applies ML-driven predictive analytics on a rich, expertly curated proprietary database to enable users to:

  • Apply a consistent and data-driven probability of success estimate on programs (transition to clinical stage, transition across phases, regulatory approval)
  • Evaluate the key drivers behind the PTRS assessments by indication and phase
  • Review analogs and benchmarks in a fast, systematic, consistent manner
  • Provide a unique data-driven perspective as an input to the semi- annual discussions and decisions of Porfolio Review Committee

Impact

>85%

Accuracy (sensitivity and specificity) in assessing the probability of success of programs as early as in Ph1

>55%

Faster compilation of data-driven, systematic assessment of internal programs

>5%

Potential revenue upside by moving most promising programs faster across clinical development
Download PDF